Amgen

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.

Enlaza Therapeutics is a biotechnology research company founded in 2020 and based in La Jolla, California. The company focuses on developing novel protein therapeutics aimed at providing more effective and safer treatment options for patients. Utilizing advanced synthetic biology technology, Enlaza's platform enables site-specific covalent coupling driven by drug binding. This innovative approach allows for the creation of first-in-class covalent biologics, which are designed to offer enhanced efficacy and improved safety profiles compared to existing treatments.

Quantinuum is a leading quantum computing company focused on advancing quantum computers and developing software solutions across various industries, including materials discovery, cybersecurity, chemistry, finance, and optimization. With a workforce of nearly 500 professionals, including over 370 scientists and engineers, Quantinuum is at the forefront of the quantum computing revolution. The company offers an open-access, architecture-independent quantum software stack and a development platform that facilitates seamless collaboration among researchers and developers. This enables them to address complex challenges and drive innovation in next-generation quantum applications, including artificial intelligence.

Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative treatments using its proprietary peptide-based technology platform, known as the Feldan Shuttle. This platform facilitates fast and safe intracellular delivery, allowing access to cellular components that are typically unreachable by conventional drugs. By leveraging the unique characteristics of the Feldan Shuttle, the company aims to create a new generation of therapeutic applications, as evidenced by its ongoing pipeline of clinical programs. Feldan Therapeutics is committed to advancing the field of intracellular therapeutics to improve patient outcomes.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

Casma Therapeutics, Inc. specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy and lysosomal flux. By focusing on enhancing autophagy, the company aims to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing the progression of various diseases. Its research targets several serious medical conditions, including lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration. Founded in 2017 and based in Cambridge, Massachusetts, Casma Therapeutics is dedicated to creating effective treatment options that meet significant unmet medical needs in the field of drug discovery and development.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

ImmunoScape is a company specializing in immunomics, focusing on immune profiling and the characterization of the human immune response with high precision. Its Deep Immunomics platform integrates advanced technologies such as mass cytometry, single cell sequencing, and proprietary computational bioinformatics to deliver detailed immune profiling information. This platform is particularly valuable in therapeutic areas like oncology and infectious diseases, where it aids in understanding the safety and efficacy of immunotherapies and in identifying potential drug targets. Additionally, ImmunoScape offers a software suite that includes immune cell profiling technologies and antigen-specific T-cell identification, providing crucial insights for companies involved in the research and clinical development of immunotherapies.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, founded in 2019. The company specializes in developing an automated platform that combines a wet laboratory with artificial intelligence and machine learning techniques for the production and characterization of antibodies. This innovative platform empowers drug developers to engineer antibodies and other therapeutic proteins with improved biophysical properties and complex functions. By leveraging AI-guided design capabilities, BigHat aims to create safer and more effective treatments for patients facing challenging diseases, thereby advancing the field of biotherapeutics.

Kernal Biologics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on designing and developing mRNA immunotherapies for diseases such as COVID-19 and cancer. Founded in 2016, the company utilizes its mRNA platform to enable specific cells to produce their own therapeutic agents. Kernal's innovative approach has garnered recognition, including awards from notable organizations like Amgen and NASA. The team behind Kernal Biologics has strong ties to prestigious institutions such as MIT and Harvard, along with extensive experience in the biotech sector, which underpins their expertise in the mRNA field.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Olive Diagnostics has developed an innovative passive urine analysis sensor that can be mounted on any toilet, enabling continuous health monitoring through urinalysis. This sensor utilizes a combination of spectroscopy and artificial intelligence to analyze the urine stream and provide real-time health alerts to users. By uploading data to a cloud-based platform, Olive Diagnostics facilitates ongoing biomarker tracking for various health indicators such as hydration, alcohol levels, pregnancy, and ovulation. This technology not only empowers individuals to gain insights into their health and body functions but also offers pharmaceutical and clinical research organizations a reliable method to monitor drug compliance and usage. By making urine lab services accessible at home, Olive Diagnostics aims to enhance disease detection and chronic disease management, particularly benefiting users in nonindustrial nations.

TileDB, Inc. develops and maintains a system for managing multi-dimensional array data, particularly suited for scientific applications. The company's offerings include TileDB Embedded, a storage engine, and TileDB Cloud, which facilitates the management of array data in the cloud. Designed to handle a variety of data types, including unstructured multimodal data, TileDB addresses the complexities encountered in fields such as genomics, biomedical imaging, and multiomic data analysis. This foundational software is utilized by research teams in pharmaceuticals and biotechnology to enhance their data platforms and drive scientific discovery. Founded in 2017 and headquartered in Cambridge, Massachusetts, TileDB also has a location in Athens, Greece.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

CancerIQ is a precision health technology company that provides a platform designed to assist healthcare providers in identifying and managing patients at high risk for cancer. The platform features predictive analytics and screening tools to help clinicians detect at-risk patients early. It includes a comprehensive library of evidence-based guidelines and risk models, which aids providers in interpreting data and guiding patients toward appropriate genetic testing, screening, and treatment interventions. Additionally, CancerIQ offers a digital genetic test ordering system and patient management tools, enhancing clinician efficiency and improving patient outcomes by facilitating early cancer detection and adherence to evidence-based care strategies.

Accure Health is a privately held precision medicine company dedicated to developing AI-powered solutions that utilize patients' biomarker profiles. The company aims to enhance the delivery of precision therapies by ensuring that treatments are directed to the appropriate cells for the right patients. Accure Health's patented technologies integrate advanced protein design, an automated biomarker device, and a scalable, food-based production system. This innovative approach focuses on improving the targeted delivery of RNA and protein therapeutics, thereby facilitating access to more effective treatments tailored to individual patient needs.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

TeneoBio, Inc. is a biotechnology company focused on developing human heavy chain antibodies, known as UniAbs, for therapeutic applications in cancer, autoimmunity, and infectious diseases. Since its founding in 2009 and headquartered in Menlo Park, California, the company has advanced several products targeting conditions such as multiple myeloma, prostate cancer, immune disorders, and AIDS. TeneoBio utilizes its proprietary antibody discovery platform, which includes genetically engineered animals and advanced technologies like next-generation sequencing and bioinformatics. This platform enables the rapid identification of unique binding molecules, facilitating the development of bispecific and trispecific antibodies as well as immune checkpoint inhibitors. The company aims to enhance patients' immune responses to overcome various diseases and disorders.

GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.

Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b (FGFR2b), currently in Phase 3 clinical trials for gastric and gastroesophageal junction cancer. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, also in Phase 1a/1b trials. Additionally, Cabiralizumab, which inhibits colony stimulating factor-1 receptor, is undergoing Phase Ia/Ib trials in combination with other therapies. The company employs its ProScreen Engine to systematically screen all relevant human proteins, enabling rapid and high-quality therapeutic development. Five Prime Therapeutics has established collaborations and license agreements with several pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, the company continues to focus on advancing novel therapies for challenging cancer indications.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

NoviSci is a software analytics and services company focused on enhancing population health outcomes, particularly for vulnerable patients with complex health conditions. The company leverages principled data science to develop tools that visualize and analyze health data through modern epidemiological methods. By employing sound scientific principles, NoviSci aims to improve the health and well-being of individuals, addressing the specific needs of populations that may be at higher risk.

DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, focuses on the design and discovery of novel therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company specializes in developing innovative therapeutics aimed at treating chronic inflammatory diseases, utilizing breakthrough technology to create first-in-class antibodies against challenging disease targets. By isolating high-quality antibodies against complex protein targets that have previously proven difficult for drug discovery, DJS Antibodies aims to provide effective treatments for conditions that are currently undruggable and untreatable.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, the company focuses on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Carmot employs a proprietary drug discovery approach known as Chemotype Evolution, which enables the exploration of novel chemical and biological frontiers. The company is advancing a portfolio of clinical-stage drug candidates, including CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist; CT-996, a once-daily oral GLP-1 receptor agonist; and CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist for treating type 1 diabetes in patients with overweight or obesity. These innovative therapies aim to enhance glucose clearance and promote weight loss, addressing the fundamental causes of metabolic diseases.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

BeiGene, Ltd. is a global biotechnology company founded in 2010, focused on the discovery and development of innovative oncology treatments aimed at improving accessibility and affordability for cancer patients worldwide. Based in Beijing, with a presence in the United States and beyond, BeiGene has established one of the largest oncology research teams globally, employing over 9,200 professionals. The company’s commercial portfolio includes BRUKINSA, a BTK inhibitor approved for various blood cancers, and Tislelizumab, an anti-PD-1 antibody currently under regulatory review for advanced esophageal squamous cell carcinoma. BeiGene's extensive pipeline encompasses a wide range of cancer therapies targeting multiple malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors. In addition to its therapeutic development, the company actively engages in programs that address the broader needs of oncology patients, such as mental health awareness initiatives. Through its commitment to innovation and patient care, BeiGene aims to significantly impact cancer treatment and improve outcomes for patients around the globe.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Keck Graduate Institute (KGI) is part of the prestigious Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field.

Otezla® is a prescription medicine approved for the treatment of patients with moderate

BeiGene, Ltd. is a global biotechnology company founded in 2010, focused on the discovery and development of innovative oncology treatments aimed at improving accessibility and affordability for cancer patients worldwide. Based in Beijing, with a presence in the United States and beyond, BeiGene has established one of the largest oncology research teams globally, employing over 9,200 professionals. The company’s commercial portfolio includes BRUKINSA, a BTK inhibitor approved for various blood cancers, and Tislelizumab, an anti-PD-1 antibody currently under regulatory review for advanced esophageal squamous cell carcinoma. BeiGene's extensive pipeline encompasses a wide range of cancer therapies targeting multiple malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors. In addition to its therapeutic development, the company actively engages in programs that address the broader needs of oncology patients, such as mental health awareness initiatives. Through its commitment to innovation and patient care, BeiGene aims to significantly impact cancer treatment and improve outcomes for patients around the globe.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cells for the treatment of cancer and autoimmune diseases. The company aims to enhance the efficacy of cell therapy by leveraging the inherent ability of NK cells to identify and eliminate abnormal cells without the need for genetic alteration. This approach allows for a broader application across various hematologic and solid tumor malignancies while potentially minimizing side effects associated with traditional T-cell therapies. Nkarta combines its NK expansion platform technology with proprietary cell engineering methods to produce a substantial supply of NK cells, enhancing their ability to recognize therapeutic targets and improving their persistence in the body for sustained activity. Through this innovative strategy, Nkarta seeks to provide more potent, well-tolerated, and rapidly available therapies for patients facing diverse cancer types.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Nuevolution is a small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a patented hybrid technology that combines wet chemistry and molecular biology to accelerate drug discovery. This platform facilitates the rapid synthesis and DNA-tagging of over 1 billion diverse small molecule compounds, allowing for efficient screening and identification of potent drug leads. Nuevolution partners with pharmaceutical and biotechnology companies, having established agreements with major firms such as Merck, GlaxoSmithKline, and Novartis. The company is also involved in a joint venture with EpiTherapeutics and ExpreS2ion Biotechnologies to develop small molecule drugs targeting epigenetic factors, supported by a project budget from the Danish High Technology Fund. Nuevolution focuses on developing treatments for oncology and inflammatory diseases and also provides contract research services, generating revenue from multiple countries, including Denmark, Sweden, and the USA. The company is privately owned by several key Scandinavian investors.

NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company focuses on developing and commercializing its proprietary NanoStraw platform technology, which facilitates direct access to the cytosol of cells. This innovative technology addresses a significant challenge in the field of cell and gene therapies by enabling the efficient and gentle delivery of various materials into difficult-to-transfect cells. Through its NanoStraw platform, NAVAN aims to enhance the capabilities of researchers in their efforts to advance therapeutic solutions.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Aetion, Inc. is a healthcare analytics company that specializes in real-world evidence (RWE) and outcomes-based analytics solutions. Founded in 2012 and based in New York City, Aetion develops the Aetion Evidence Platform, which leverages everyday clinical and financial interactions within the healthcare system to generate critical insights about the effectiveness and value of medical treatments. This platform serves a diverse clientele, including life sciences companies, payers, providers, medical device manufacturers, and academic institutions, allowing them to analyze data from various sources such as claims, electronic health records, registries, and clinical trials. Aetion’s patented rapid-cycle analytics technology facilitates real-time collaboration among stakeholders, enabling them to make informed decisions and optimize patient care. The company has formed strategic partnerships with leading organizations, including McKesson, to enhance its offerings and expand its reach in the healthcare sector.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital treatments for cognitive disorders. The company's core technology involves creating video games that not only engage users but also assess and enhance cognitive abilities. Akili's pipeline focuses on treating and improving symptoms associated with various medical conditions, including ADHD, MDD, ASD, and inflammatory diseases.

Aetion, Inc. is a healthcare analytics company that specializes in real-world evidence (RWE) and outcomes-based analytics solutions. Founded in 2012 and based in New York City, Aetion develops the Aetion Evidence Platform, which leverages everyday clinical and financial interactions within the healthcare system to generate critical insights about the effectiveness and value of medical treatments. This platform serves a diverse clientele, including life sciences companies, payers, providers, medical device manufacturers, and academic institutions, allowing them to analyze data from various sources such as claims, electronic health records, registries, and clinical trials. Aetion’s patented rapid-cycle analytics technology facilitates real-time collaboration among stakeholders, enabling them to make informed decisions and optimize patient care. The company has formed strategic partnerships with leading organizations, including McKesson, to enhance its offerings and expand its reach in the healthcare sector.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Fortuna Fix Inc. is a clinical biotechnology company based in Laval, Canada, established in 2015. The company specializes in developing innovative technologies aimed at restoring full neuronal functionality for patients suffering from neurodegenerative diseases and neurotrauma. Fortuna Fix utilizes a direct cell reprogramming technology platform and proprietary bio-scaffolding technology to enhance treatment options. Its primary focus lies in lead programs addressing spinal cord injury and Parkinson's disease, while also pursuing developments in areas such as stroke, traumatic brain injury, hearing loss, and amyotrophic lateral sclerosis (ALS). By advancing ethical regenerative medicine, Fortuna Fix aims to significantly improve patient outcomes in these challenging medical conditions.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Darmiyan, Inc. is a company that specializes in the development of diagnostic software aimed at the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders. Based in San Francisco and founded in 2014, the company offers BrainSee, a Software as a Service platform that utilizes non-invasive brain MRI scans to produce detailed brain maps. This innovative tool quantifies neurodegeneration in individual brain voxels and generates a summary score reflecting brain health and the risk of cognitive decline. BrainSee operates using proprietary technology, referred to as The Virtual Microscope, which provides insights into brain cell distortion before clinical symptoms manifest. The algorithm has undergone successful third-party validation in the US and Canada, demonstrating its accuracy in predicting mild cognitive impairment. By leveraging advanced medical imaging and artificial intelligence, Darmiyan aims to enhance early diagnosis and intervention for patients with neurodegenerative diseases.

WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. The company aims to address the limitations of existing pain management therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, by creating safer and more effective alternatives. Their lead candidates are highly selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is crucial in the generation and conduction of pain signals. By targeting this channel, SiteOne Therapeutics seeks to provide healthcare professionals with advanced treatment options for neuropathic pain, ultimately improving patient outcomes and efficiency in pain management.

eHealth Ventures, established in 2014, is an Israeli-based accelerator/incubator firm specializing in digital health. It focuses on investing in and nurturing early-stage companies within the digital therapeutics and diagnostics sectors. The firm leverages significant government funding and backing from prominent venture capital funds and a technological incubator.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital treatments for cognitive disorders. The company's core technology involves creating video games that not only engage users but also assess and enhance cognitive abilities. Akili's pipeline focuses on treating and improving symptoms associated with various medical conditions, including ADHD, MDD, ASD, and inflammatory diseases.

Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

Unilife is a U.S.-based medical device and technology company that specializes in designing, developing, and manufacturing innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that features smart, reusable auto-injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies packaged in standard prefilled barrels, catering to the needs of pharmaceutical and biotechnology companies that produce injectable biologics, drugs, and vaccines. Unilife's focus on differentiated delivery systems aims to improve patient experiences and outcomes in medication administration.

Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.

Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company is known for its innovative approach in creating a cholesteryl ester transfer protein inhibitor, which serves as a pharmacological therapy to reduce low-density lipoprotein cholesterol levels. By lowering these cholesterol levels, Dezima Pharma aims to provide clinicians with effective treatment options for patients suffering from dyslipidemia and related cardiovascular conditions.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing therapeutics for diseases associated with the overactivation of the complement system. Utilizing a peptide chemistry platform, the company creates synthetic macrocyclic peptides that combine the specificity of antibodies with the pharmacological advantages of small molecules. Its lead candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, along with a Phase Ib trial for patients with renal impairment. Additionally, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and other complement factors for various diseases. The company has established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for non-complement cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

Ziarco, Inc. is a biotechnology company founded in 2012 and based in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and its product pipeline includes a histamine H4 receptor antagonist program targeting various conditions such as asthma, allergic rhinitis, pruritus, skin diseases, and pain. Ziarco's innovations aim to provide effective treatment options for patients suffering from atopic dermatitis and psoriasis, enhancing their quality of life through improved therapeutic solutions.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. This technology is designed to enhance the immune system's ability to generate specific responses to targeted antigens, which is crucial for effective cancer treatment and other immune-mediated diseases. NexImmune's product offerings include AIM101, an injectable therapy for certain solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in human trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. By focusing on improving the body's T cell responses, NexImmune aims to provide curative therapies for patients facing life-threatening conditions.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Onyx Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company's primary product is Nexavar, an oral multiple kinase inhibitor designed to target proteins that contribute to tumor cell proliferation and angiogenesis. By concentrating on improving the quality of life for cancer patients, Onyx Pharmaceuticals aims to deliver effective treatment options within the competitive landscape of oncology.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

DeCODE Genetics is a biopharmaceutical company based in Reykjavik, Iceland, founded in 1996. It focuses on analyzing the human genome to identify genetic variants associated with common diseases. The company utilizes population studies to uncover key genetic risk factors for various conditions, including cardiovascular disease and cancer. DeCODE Genetics develops diagnostic tests and technologies aimed at improving the treatment, diagnosis, and prevention of these diseases. By leveraging its expertise in chemistry and structural biology, the company also supports clients in the healthcare sector with DNA-based reference laboratory tests and consumer genome analysis services, which help assess individual risk for common diseases.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

MN is the leading supplier of pharmaceuticals to hospitals in Turkey and garnered sales of about $200 million last year, according to the statement. It was the first Turkish pharmaceutical company to win a license from the Food and Drug Administration to sell products in the U.S.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.